Climb Bio annual free cash flow
2023
2024
2025
Climb Bio Free Cash Flow (FCF) History (CLYM)
Climb Bio reported −$54.5M in free cash flow for fiscal 2025, a decrease of $39.0M from the previous fiscal year.
View full Climb Bio company overviewClimb Bio free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$54.5M | −$39.0M | — | — |
| 2024 | 2024-12-31 | −$15.6M | $5.0M | — | — |
| 2023 | 2023-12-31 | −$20.6M | — | — | — |
Climb Bio quarterly free cash flow
Q3.23
Q3.24
Q3.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$12.2M | — | — | — |
| Q3 2024 | 2024-09-30 | −$7.6M | — | — | — |
| Q3 2023 | 2023-09-30 | $3.5M | — | — | — |
Climb Bio free cash flow growth trends
Climb Bio's latest reported quarter, Q3 2025, generated −$12.2M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Climb Bio filings at SEC.gov ↗